Arjuna Capital boosted its position in shares of Novartis AG (NYSE:NVS) by 1.6% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 17,150 shares of the company’s stock after purchasing an additional 277 shares during the quarter. Novartis comprises about 1.3% of Arjuna Capital’s holdings, making the stock its 26th biggest holding. Arjuna Capital’s holdings in Novartis were worth $1,649,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in NVS. Pathlight Investors LLC bought a new stake in shares of Novartis during the fourth quarter valued at approximately $408,000. Executive Wealth Management LLC purchased a new position in shares of Novartis in the fourth quarter valued at $36,000. Wambolt & Associates LLC grew its holdings in shares of Novartis by 8.0% in the first quarter. Wambolt & Associates LLC now owns 8,256 shares of the company’s stock valued at $689,000 after purchasing an additional 609 shares in the last quarter. Crawford Investment Counsel Inc. grew its holdings in shares of Novartis by 8.9% in the first quarter. Crawford Investment Counsel Inc. now owns 2,581 shares of the company’s stock valued at $248,000 after purchasing an additional 212 shares in the last quarter. Finally, Nwam LLC grew its holdings in shares of Novartis by 13.7% in the first quarter. Nwam LLC now owns 3,623 shares of the company’s stock valued at $348,000 after purchasing an additional 437 shares in the last quarter. 11.80% of the stock is currently owned by institutional investors.
Shares of NVS traded down $2.06 during trading hours on Friday, reaching $90.44. 1,371,647 shares of the company traded hands, compared to its average volume of 1,585,927. The stock has a market capitalization of $207.50 billion, a price-to-earnings ratio of 17.77, a price-to-earnings-growth ratio of 2.17 and a beta of 0.59. Novartis AG has a 12-month low of $67.00 and a 12-month high of $93.65. The company has a current ratio of 0.93, a quick ratio of 0.83 and a debt-to-equity ratio of 0.48. The stock has a fifty day moving average of $88.58.
NVS has been the subject of a number of recent research reports. Morgan Stanley lowered shares of Novartis from an “equal weight” rating to an “underweight” rating and raised their target price for the company from $82.50 to $82.52 in a report on Wednesday, April 10th. Guggenheim raised shares of Novartis from a “neutral” rating to a “buy” rating and set a $79.16 target price for the company in a report on Wednesday, April 24th. JPMorgan Chase & Co. reissued a “sell” rating on shares of Novartis in a report on Friday. Zacks Investment Research lowered shares of Novartis from a “hold” rating to a “strong sell” rating in a research note on Thursday, April 11th. Finally, Liberum Capital raised shares of Novartis from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Five equities research analysts have rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Novartis currently has a consensus rating of “Hold” and an average price target of $87.57.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Featured Story: How is a buy-side analyst different from a sell-side analyst?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.